Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-7: Zimberelimab, Domvanalimab, and Etrumadenant in Front-Line NSCLC
NCT04262856Phase 2Completed
- Sponsor
- Arcus Biosciences
- Start
- May 2020
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of domvanalimab, etrumadenant and zimberelimab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Arcus Biosciences. Primary endpoints: Objective Response Rate and Progression-Free Survival. Started May 2020; status: completed.
02
Drugs
domvanalimabetrumadenantzimberelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04262856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262856.